With 1.53 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $14.98 whereas the lowest price it dropped to was $14.36. The 52-week range on ARQT shows that it touched its highest point at $15.79 and its lowest point at $3.11 during that stretch. It currently has a 1-year price target of $19.00. Beta for the stock currently stands at 1.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARQT was down-trending over the past week, with a drop of -2.08%, but this was up by 19.15% over a month. Three-month performance surged to 43.69% while six-month performance rose 39.37%. The stock gained 273.91% in the past year, while it has gained 4.95% so far this year. A look at the trailing 12-month EPS for ARQT yields -1.79 with Next year EPS estimates of -0.99. For the next quarter, that number is -0.29. This implies an EPS growth rate of 64.22% for this year and 27.08% for next year. EPS is expected to grow by 9.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -48.07%.
Float and Shares Shorts:
At present, 117.00 million ARQT shares are outstanding with a float of 102.97 million shares on hand for trading. On 2024-12-13, short shares totaled 23.11 million, which was 1975.0 higher than short shares on 1731628800. In addition to Mr. Todd Franklin Watanabe M.A. as the firm’s President, CEO & Director, Dr. Bhaskar Chaudhuri Ph.D. serves as its Co-Founder & Independent Director.
Institutional Ownership:
Through their ownership of 1.13598 of ARQT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ARQT reported revenue of $44755000.0 and operating income of -$39066000.0. The EBITDA in the recently reported quarter was -$33452000.0 and diluted EPS was -$0.33.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARQT since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ARQT analysts setting a high price target of 29.0 and a low target of 12.0, the average target price over the next 12 months is 19.0. Based on these targets, ARQT could surge 98.36% to reach the target high and fall by -17.92% to reach the target low. Reaching the average price target will result in a growth of 29.96% from current levels.
Analysts have provided yearly estimates in a range of -$1.23316 being high and -$1.40222 being low. For ARQT, this leads to a yearly average estimate of -$1.3525.
